MX2023009371A - Seleccion de neoepitopos como objetivos especificos de enfermedad para terapia con eficacia mejorada. - Google Patents
Seleccion de neoepitopos como objetivos especificos de enfermedad para terapia con eficacia mejorada.Info
- Publication number
- MX2023009371A MX2023009371A MX2023009371A MX2023009371A MX2023009371A MX 2023009371 A MX2023009371 A MX 2023009371A MX 2023009371 A MX2023009371 A MX 2023009371A MX 2023009371 A MX2023009371 A MX 2023009371A MX 2023009371 A MX2023009371 A MX 2023009371A
- Authority
- MX
- Mexico
- Prior art keywords
- neoepitopes
- disease
- specific targets
- therapy
- enhanced efficacy
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000037451 immune surveillance Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
La presente invención se refiere a métodos para determinar si los neoepítopos que sólo están expresados en o sobre células enfermas son objetivos específicos de enfermedad adecuados, de tal manera que sea menos probable que la célula enferma sea capaz de escapar la vigilancia inmunológica, y utilizar los neoepítopos para proporcionar una respuesta inmune contra células enfermas que expresan los neoepítopos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016067348 | 2016-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009371A true MX2023009371A (es) | 2023-08-16 |
Family
ID=59399416
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000733A MX2019000733A (es) | 2016-07-20 | 2017-07-19 | Seleccion de neoepitopos como objetivos especificos de enfermedad para terapia con eficacia mejorada. |
| MX2023009369A MX2023009369A (es) | 2016-07-20 | 2019-01-17 | Seleccion de neoepitopos como objetivos especificos de enfermedad para terapia con eficacia mejorada. |
| MX2023009371A MX2023009371A (es) | 2016-07-20 | 2019-01-17 | Seleccion de neoepitopos como objetivos especificos de enfermedad para terapia con eficacia mejorada. |
| MX2023009370A MX2023009370A (es) | 2016-07-20 | 2019-01-17 | Seleccion de neoepitopos como objetivos especificos de enfermedad para terapia con eficacia mejorada. |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000733A MX2019000733A (es) | 2016-07-20 | 2017-07-19 | Seleccion de neoepitopos como objetivos especificos de enfermedad para terapia con eficacia mejorada. |
| MX2023009369A MX2023009369A (es) | 2016-07-20 | 2019-01-17 | Seleccion de neoepitopos como objetivos especificos de enfermedad para terapia con eficacia mejorada. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009370A MX2023009370A (es) | 2016-07-20 | 2019-01-17 | Seleccion de neoepitopos como objetivos especificos de enfermedad para terapia con eficacia mejorada. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20190189241A1 (es) |
| EP (2) | EP3488443B8 (es) |
| JP (2) | JP7171543B2 (es) |
| KR (2) | KR102516166B1 (es) |
| CN (2) | CN109477149A (es) |
| AU (1) | AU2017299162A1 (es) |
| BR (1) | BR112018077122A8 (es) |
| CA (1) | CA3031003A1 (es) |
| CY (1) | CY1124551T1 (es) |
| DK (1) | DK3488443T3 (es) |
| ES (1) | ES2890424T3 (es) |
| HR (1) | HRP20211443T1 (es) |
| HU (1) | HUE056660T2 (es) |
| IL (2) | IL311369A (es) |
| LT (1) | LT3488443T (es) |
| MX (4) | MX2019000733A (es) |
| PL (1) | PL3488443T3 (es) |
| PT (1) | PT3488443T (es) |
| RS (1) | RS62390B1 (es) |
| SG (2) | SG10201912678QA (es) |
| SI (1) | SI3488443T1 (es) |
| WO (1) | WO2018015433A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117224710A (zh) | 2017-02-01 | 2023-12-15 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
| EP3666887A4 (en) * | 2017-08-10 | 2021-09-01 | Good T Cells, Inc. | METHOD OF ACTIVATING T CELLS FOR CANCER TREATMENT |
| WO2019075251A2 (en) * | 2017-10-12 | 2019-04-18 | Nantomics, Llc | CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS |
| CN109294983A (zh) * | 2018-09-30 | 2019-02-01 | 北京鼎成肽源生物技术有限公司 | 一种lff2细胞 |
| CN111402954B (zh) * | 2019-01-02 | 2023-07-21 | 中国人民解放军军事科学院军事医学研究院 | 一种辨识与预测空间辐射损伤防护药靶相关人类基因的方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| JP2002515734A (ja) | 1996-01-02 | 2002-05-28 | カイロン コーポレイション | 遺伝子改変された樹状細胞により媒介される免疫刺激 |
| ATE449193T1 (de) | 2006-04-12 | 2009-12-15 | Medical Res Council | Verfahren zur bestimmung der kopienummer |
| JP2010537200A (ja) | 2007-08-21 | 2010-12-02 | ワシントン ユニバーシティー | 改善されたアルツハイマー診断法 |
| BRPI0816393A2 (pt) | 2007-09-07 | 2015-03-03 | Fluidigm Corp | Método para determinar o número de cópias relativo de uma sequência de polinucleotídeo alvo em um genoma de um indivíduo |
| KR102315754B1 (ko) | 2010-05-14 | 2021-10-22 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| RS64230B1 (sr) * | 2011-05-24 | 2023-06-30 | BioNTech SE | Individualizovane vakcine protiv kancera |
| CN104080797A (zh) * | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
| US9569586B2 (en) * | 2012-02-13 | 2017-02-14 | Albert Rubben | Algorithm for modification of somatic cancer evolution |
| EP2835752B8 (en) | 2012-04-05 | 2018-12-26 | BGI Genomics Co., Ltd. | Method and system for detecting copy number variation |
| AU2013289939B2 (en) * | 2012-07-12 | 2018-08-09 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
| CA2878246C (en) | 2012-07-20 | 2022-01-11 | Verinata Health, Inc. | Detecting and classifying copy number variation in a cancer genome |
| EP2984598A1 (en) | 2013-03-06 | 2016-02-17 | Life Technologies Corporation | Systems and methods for determining copy number variation |
| KR20230145545A (ko) * | 2013-04-07 | 2023-10-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 개인맞춤화 신생물 백신을 위한 조성물 및 방법 |
| US20150331992A1 (en) * | 2014-05-15 | 2015-11-19 | Ramot At Tel-Aviv University Ltd. | Cancer prognosis and therapy based on syntheic lethality |
| JP2018535202A (ja) | 2015-10-12 | 2018-11-29 | ナントミクス，エルエルシー | ネオエピトープの反復発見と適応可能な免疫療法およびその方法 |
| TWI765875B (zh) * | 2015-12-16 | 2022-06-01 | 美商磨石生物公司 | 新抗原辨識、製造及用途 |
| US20190247435A1 (en) * | 2016-06-29 | 2019-08-15 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
-
2017
- 2017-07-19 WO PCT/EP2017/068226 patent/WO2018015433A2/en unknown
- 2017-07-19 KR KR1020197002010A patent/KR102516166B1/ko active IP Right Grant
- 2017-07-19 EP EP17743311.7A patent/EP3488443B8/en active Active
- 2017-07-19 SG SG10201912678QA patent/SG10201912678QA/en unknown
- 2017-07-19 LT LTEPPCT/EP2017/068226T patent/LT3488443T/lt unknown
- 2017-07-19 CN CN201780044824.0A patent/CN109477149A/zh active Pending
- 2017-07-19 PT PT177433117T patent/PT3488443T/pt unknown
- 2017-07-19 ES ES17743311T patent/ES2890424T3/es active Active
- 2017-07-19 PL PL17743311T patent/PL3488443T3/pl unknown
- 2017-07-19 MX MX2019000733A patent/MX2019000733A/es unknown
- 2017-07-19 JP JP2019502699A patent/JP7171543B2/ja active Active
- 2017-07-19 CA CA3031003A patent/CA3031003A1/en active Pending
- 2017-07-19 EP EP21178672.8A patent/EP3967324A1/en active Pending
- 2017-07-19 SG SG11201900132QA patent/SG11201900132QA/en unknown
- 2017-07-19 KR KR1020237002958A patent/KR20230019223A/ko not_active Application Discontinuation
- 2017-07-19 HR HRP20211443TT patent/HRP20211443T1/hr unknown
- 2017-07-19 US US16/318,895 patent/US20190189241A1/en active Pending
- 2017-07-19 HU HUE17743311A patent/HUE056660T2/hu unknown
- 2017-07-19 SI SI201730919T patent/SI3488443T1/sl unknown
- 2017-07-19 CN CN202311634920.4A patent/CN117757931A/zh active Pending
- 2017-07-19 BR BR112018077122A patent/BR112018077122A8/pt unknown
- 2017-07-19 IL IL311369A patent/IL311369A/en unknown
- 2017-07-19 AU AU2017299162A patent/AU2017299162A1/en active Pending
- 2017-07-19 RS RS20211138A patent/RS62390B1/sr unknown
- 2017-07-19 IL IL264203A patent/IL264203B1/en unknown
- 2017-07-19 DK DK17743311.7T patent/DK3488443T3/da active
-
2019
- 2019-01-17 MX MX2023009369A patent/MX2023009369A/es unknown
- 2019-01-17 MX MX2023009371A patent/MX2023009371A/es unknown
- 2019-01-17 MX MX2023009370A patent/MX2023009370A/es unknown
-
2021
- 2021-09-14 CY CY20211100808T patent/CY1124551T1/el unknown
-
2022
- 2022-11-02 JP JP2022176504A patent/JP2023009120A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023009369A (es) | Seleccion de neoepitopos como objetivos especificos de enfermedad para terapia con eficacia mejorada. | |
| PH12018500494A1 (en) | Car t cell therapies with enhanced efficacy | |
| TN2018000138A1 (en) | Point mutations in trk inhibitor-resistant cancer and methods relating to the same | |
| AU2017260389A1 (en) | Chimeric neurotoxins | |
| EP3328399A4 (en) | Modified cells and methods of therapy | |
| MX2020010194A (es) | Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas. | |
| WO2018068008A8 (en) | T cells expressing membrane-anchored il-12 for the treatment of cancer | |
| EP3568467A4 (en) | MODIFIED T LYMPHOCYTES AND THEIR METHODS OF USE | |
| EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
| AU366296S (en) | Earphone | |
| MY187540A (en) | Compounds active towards bromodomains | |
| EP3149597A4 (en) | Electromagnetic threat detection and mitigation in the internet of things | |
| PH12019501010A1 (en) | Arginase inhibitor combination therapies | |
| EP3558395A4 (en) | TUMOR AND IMMUNE CELL IMAGING ON THE BASIS OF PD-L1 EXPRESSION | |
| EP3468565A4 (en) | USE OF MI R-198 FOR THE TREATMENT AND DIAGNOSIS OF SKIN PLATEN CARCINOMA | |
| BR112016025040A2 (pt) | métodos para determinar a expressão de biomarcador mit, para tratar câncer, para identificar um indivíduo com câncer, para predizer se um indivíduo com câncer tem mais ou menos probabilidade de responder efetivamente ao tratamento, para inibir a proliferação de uma célula e para tratar nccrcc em um indivíduo | |
| EP3161129A4 (en) | Neural cells expressing adenovirus e4orf1, and methods of making and using the same | |
| EP3344760A4 (en) | GENETICALLY MODIFIED T CELLS RESISTANT TO MEDICAMENTS AND METHODS OF USE | |
| IL275507A (en) | Methods based on the identification of foci of RAD51 in tumor cells | |
| WO2020008489A3 (en) | Aptamers for use in the therapy, prevention, diagnosis and detection of the papillomavirus | |
| WO2018112449A3 (en) | Live cell imaging systems and methods to validate triggering of immune response | |
| AU360939S (en) | Metal knife block face plate | |
| WO2017011559A8 (en) | Compositions and methods for treating cancer | |
| AU363633S (en) | Oyster opener | |
| EP3529622A4 (en) | GENETICALLY CODED CELL DEATH INDICATORS AND METHOD FOR USE THEREOF |